Figure 1
Figure 1. WBC response to MK-0457 therapy in a patient with imatinib- and nilotinib-resistant T315I BCR-ABL–positive CML.

WBC response to MK-0457 therapy in a patient with imatinib- and nilotinib-resistant T315I BCR-ABL–positive CML.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal